[(4-methoxyphenyl)sulfonyl]carbonimidodithioic acid dimethyl ester | 93420-43-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(4-methoxyphenyl)sulfonyl]carbonimidodithioic acid dimethyl ester
• 英文别名: N-(bis[methylsulfanyl]methylene)-4-methoxy-benzenesulfonamide；N-[bis(methylsulfanyl)methylidene]-4-methoxybenzenesulfonamide
• CAS: 93420-43-0
• 化学式: C₁₀H₁₃NO₃S₃
• 分子量: 291.416
• InChiKey: CCDFIDPCJSFAHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  115
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [(4-methoxyphenyl)sulfonyl]carbonimidodithioic acid dimethyl ester 以 乙醇 为溶剂， 反应 208.0h， 生成 9,22-bis(p-methoxyphenylsulfonylimino)-1,4,14,17-tetraoxa-8,10,21,23-tetraazacyclohexacosane
  参考文献：
  名称：

  Syntheses of 9-Phenylsufonylimino-1,4-dioxa-8,10-diazacyclotridecanes and 9,22-Bis(phenylsulfonylimino)-1,4,14,17-tetraoxa-8,10,21,23-tetraazacyclohexacosanes: Macrocyclization via Dimethyl N-Phenylsulfonylcarbonimidodithioates.

  摘要：

  N-苯基磺酰基二硫代碳亚胺二甲酯（1）与二胺反应后，由于起始原料摩尔比的变化，产生了三种不同类型的产物。从脂肪族二胺中得到了杂环 1 : 1 和无环 2 : 1 反应产物。为了制备大环，1 与 1,10-二氨基-4,7-二氧二十烷（10）发生了反应。通过 1 与 10 的 2 : 1 和 1 : 2 混合反应，分别得到了 1,1′-(4,7-二氧代十亚基)双(2-甲基-3-苯磺酰基异硫脲)(11) 和 9-苯磺酰亚胺-1,4-二氧杂-8,10-二氮杂环十三烷。2 : 2 反应产物 9,22-双（苯磺酰亚胺）-1,4,14,17-四氧杂-8,10,21,23-四氮杂环己烷是由 1 和过量的二胺 10（1 : 4）或 11 和二胺 10 制得的。

  DOI：

  10.1246/bcsj.66.148
• 作为产物：
  描述：

  二硫化碳 、 对甲氧基苯磺酰胺 、 硫酸二甲酯 在 sodium hydroxide 作用下， 生成 [(4-methoxyphenyl)sulfonyl]carbonimidodithioic acid dimethyl ester
  参考文献：
  名称：

  Regiospecific Synthesis ofN-Sulfonyl Derivatives of 3,5-Diamino-1H-1, 2,4-triazole and 2,5-Diamino-1,3,4-thiadiazole

  摘要：

  将 S,S-二甲基 N-（烷基磺酰基）碳二硫亚胺酸盐 1 与氨基胍碳酸氢盐和硫代肼酰胺缩合，可分别得到 3,5-二氨基-1H-1,2,4-三唑 2 和 2,5-二氨基-1,3,4-噻二唑 3 的 N-磺酰基衍生物的特异性合成。

  DOI：

  10.1055/s-1991-26426

文献信息

• (+)-Saxitoxin:  A First and Second Generation Stereoselective Synthesis
  作者：James J. Fleming、Matthew D. McReynolds、J. Du Bois

  DOI：10.1021/ja071501o

  日期：2007.8.1

  A stereoselective synthesis of the bis-guanidinium toxin (+)-saxitoxin (STX), the agent infamously associated with red tides and paralytic shellfish poisoning, is described. Our approach to this unique natural product advances through an unusual nine-membered ring guanidine intermediate 39 en route to the tricyclic skeleton that defines STX. The effectiveness of this strategy is notable, as only four

  描述了双胍毒素 (+)-石房蛤毒素 (STX) 的立体选择性合成，该试剂臭名昭著地与赤潮和麻痹性贝类中毒有关。我们对这种独特的天然产物的研究通过一种不寻常的九元环胍中间体 39 推进到定义 STX 的三环骨架。该策略的有效性是显着的，因为只需四个步骤即可将 39 转化为目标分子，包括由 OsCl3 催化的四电子烯烃氧化。关键单环胍的构建是通过两个通道实现的，第一个通道利用 Rh 催化的 CH 胺化，并突出了一类新型杂环 N,O-缩醛作为用于制作功能化胺的亚胺离子等价物。
• [EN] ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS<br/>[FR] DÉRIVÉS DE CARBOXAMIDINE DE PYRAZOLINE ARYLSULFONYLIQUE FORMANT DES ANTAGONISTES DE 5-HT6
  申请人：SOLVAY PHARM BV

  公开号：WO2009115515A1

  公开（公告）日：2009-09-24

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5- HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  这项发明涉及芳基磺酰基吡唑啉羧酰胺衍生物作为5-HT6受体拮抗剂，以及用于制备这些化合物的方法和用于它们合成的新型中间体。该发明还涉及这些化合物和组合物的用途，特别是它们在向患者施用以达到在帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑、抑郁症、躁郁症、精神病、癫痫、强迫性障碍、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知下降、轻度认知障碍、睡眠障碍、进食障碍、厌食症、暴食症、暴食症、恐慌发作、不安定症、注意力缺陷多动障碍、注意力缺陷障碍、戒除可卡因、乙醇、尼古丁或苯二氮卓类药物滥用、疼痛、与脊柱损伤或头部损伤相关的障碍、脑积水、功能性肠道障碍、肠易激综合征、肥胖和2型糖尿病中的治疗效果方面的应用。这些化合物具有一般公式（1），其中符号的含义如描述中所示。
• ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Loevezijn Arnold Van

  公开号：US20110046171A1

  公开（公告）日：2011-02-24

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  本发明涉及芳基磺酰基吡唑啉羧酰胺衍生物，其作为5-ht6受体拮抗剂，以及用于制备这些化合物的方法和有用于它们的合成的新型中间体。该发明还涉及这些化合物和组合物的用途，特别是它们用于给患者治疗帕金森病、亨廷顿病、精神分裂症、焦虑症、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、年龄相关的认知下降、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安静脚症候群、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓创伤或头部损伤有关的疾病、脑积水、功能性肠道紊乱、肠易激综合征、肥胖症和2型糖尿病。这些化合物具有通式（1），其中符号的含义如描述中所给。
• ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：AbbVie Bahamas Limited

  公开号：US20150051239A1

  公开（公告）日：2015-02-19

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  本发明涉及苯磺酰基吡唑啉羧酰胺衍生物作为5-ht6受体拮抗剂，以及制备这些化合物的方法和用于它们合成的新型中间体。本发明还涉及这些化合物和组成物的用途，特别是将它们用于治疗帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑症、抑郁症、躁郁症、精神病、癫痫、强迫症、情感障碍、偏头痛、阿尔茨海默病、与年龄相关的认知下降、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安静脚症候群、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮卓类药物的滥用、疼痛、与脊髓损伤或头部损伤相关的疾病、脑积水、功能性肠道紊乱、肠易激综合征、肥胖症和2型糖尿病等方面。这些化合物具有通式（1），其中符号的含义在说明中给出。
• Synthesis and tautomerism of 1-arylsulfonamido-1-methylthio-2-nitroethylenes: Conversion to n-arylsulfonyl nitroacetamides
  作者：S.P Maybhate、A.R.A.S Deshmukh、S Rajappa

  DOI：10.1016/s0040-4020(01)80911-x

  日期：——

  N-Arylsulfonyl carbonimidodithioic acid dimethyl ester has been reacted with nitroalkanes to generate the corresponding 1-alkylthio-1-aryl sulfonamido-2-nitroethylenes; the latter have been hydrolysed to N-arylsulfonyl-2-nitro-acetamides. Solvent dependent imine-enamine tautomerism is observed in the nitroenamines 2a-d.

  使N-芳基磺酰基碳亚氨基二硫代酸二甲酯与硝基烷反应，生成相应的1-烷硫基-1-芳基磺酰胺基-2-硝基乙烯；后者已被水解为N-芳基磺酰基-2-硝基-乙酰胺。在亚硝基胺2a-d中观察到溶剂依赖性的亚胺-烯胺互变异构。